Cure8 research brief
Upadacitinib is a JAK inhibitor used for moderate-to-severe IBD. Changes in lipids during treatment could affect cardiovascular risk assessment for people on this medication, so patients and clinicians may need to monitor lipids and consider individual risk factors.
Patients with Crohn’s disease or ulcerative colitis starting or receiving upadacitinib; clinicians prescribing JAK inhibitors; clinicians monitoring cardiovascular risk in IBD; researchers studying IBD treatment safety.
This PubMed abstract reports a single-center retrospective cohort of 159 patients with ulcerative colitis or Crohn’s disease treated with upadacitinib and followed up to 2 years. The study measured fasting lipid panels and inflammatory markers (fecal calprotectin, CRP, hs-CRP) at baseline, end of induction (weeks 8–12), 1 year, and 2 years.
The main findings described in the abstract: total cholesterol, LDL-C, and HDL-C rose modestly after starting upadacitinib; the LDL-C/HDL-C ratio did not increase. Lipid increases correlated inversely with CRP reductions, suggesting a relationship with decreasing inflammation.
No myocardial infarction, stroke, or cardiovascular death were reported; one venous thromboembolism and three cases of hypertension were recorded. Practical takeaways The authors conclude that lipid monitoring and individualized cardiovascular risk assessment are warranted during upadacitinib therapy.
This study is observational and from a single center; it reports associations rather than proving causation.
This is a single-center, retrospective cohort described in an abstract-format PubMed entry (structured content depth: abstract). The study reports associations between lipid changes and inflammatory marker reductions; it does not establish long-term cardiovascular outcomes. The sample size and observational design limit causal inference.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Real-world data on upadacitinib help patients and clinicians understand how the drug performs outside clinical trials, including how long patients stay on treatment, remission rates, and common side effects.
This analysis summarizes longer-term safety data for upadacitinib (Rinvoq) in people with moderate to severe ulcerative colitis and Crohn’s disease.
The review compiles trial and real-world safety data for upadacitinib in IBD and highlights monitoring needs and infection risks (notably herpes zoster), which are directly relevant when choosing or managing JAK...
